ArticleReports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology2026
Tailored contact brachytherapy for challenging facial basal cell carcinomas: clinical results of 3D printing technology implementation.
Article in Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Basal cell carcinoma (BCC) often arises on cosmetically and functionally sensitive facial sites where standard contact brachytherapy applicators may not conform optimally. Patient-specific, 3D-printed surface applicators may improve geometric conformity, reduce air gaps, and enhance dose reproducibility. We report outcomes of individualized 3D-printed contact high-dose-rate brachytherapy (HDR-BT) for challenging facial BCC. Materials and methods: In this single-institution retrospective study, patients with histologically confirmed facial BCC in curved or irregular sites were treated with customized 3D-printed surface applicators. A planning computed tomography (CT) obtained with the applicator in situ guided contouring and optimization. Treatment was delivered with an Ir-192 HDR afterloader to 42-45 Gy in 6-11 fractions. Patients were evaluated at 4 weeks and then every 3-6 months. Primary endpoints were complete response (CR) and local control (LC); toxicity was graded per Radiation Therapy Oncology Group/European Organisation for Research and Treatment of Cancer (RTOG/EORTC) scale. Results: Twenty-six patients (31 lesions; median age 77 years) were treated: T1 77%, T2 13%, T3 10%. Sites: nose 81%, peri-orbital 13%, ear 6%; 58% primary, 42% postoperative recurrences. At a median follow-up of 32 months, CR and LC were 100%. Acute reactions were mainly grade 1-2 skin changes; higher-grade events were transient. Late toxicity comprised grade 1 discoloration/hypopigmentation in 52% and grade 2 telangiectasia in 23%; 25% had no late toxicity. No grade ≥ 3 late events occurred. Conclusions: Individualized 3D-printed contact applicators yielded excellent tumor control with low late toxicity in complex facial BCC. These practice-oriented data support wider implementation of personalized applicators in surface HDR-BT and encourage prospective validation in multicenter settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.